Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $52.79
    -0.48 (-0.90%)

    Market Cap: $4.95B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(24/39)
    Avg Surprise
    +205.27%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.49
    Range$-0.57 - $1.16
    8 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.40+23.7%
    60d ago$0.50-2.2%
    30d ago$0.51-4.4%
    7d ago$0.52-6.0%
    Current$0.49
    Revenue Consensus
    $196M
    Range$157M - $240M
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.93
    Range$0.20 - $2.18
    8 analysts
    Revenue Consensus
    $233M
    Range$143M - $315M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.93---
    Sep 26EST
    		-$0.49---
    Jun 26
    Reported Aug 4
    		$-0.37$-0.14-164.29%Miss-384.6%
    Mar 26
    Reported May 4
    		$0.05$-0.06+183.33%Beat+126.3%
    Dec 25
    Reported Feb 19
    		$0.37$-0.04+1025.00%Beat+178.7%
    Sep 25
    Reported Oct 30
    		$0.59$-0.08+837.50%Beat+228.3%
    Jun 25
    Reported Aug 6
    		$0.13$0.04+225.00%Beat+120.0%
    Mar 25
    Reported May 1
    		$-0.19N/A+51.28%Beat+87.4%
    Dec 24
    Reported Feb 20
    		$-0.47$-0.38-24.14%Miss+50.0%
    Sep 24
    Reported Oct 31
    		$-0.46$-0.54+14.81%Beat-120.3%
    Jun 24
    Reported Aug 1
    		$-0.65$-0.72+9.72%Beat+15.6%
    Mar 24
    Reported May 6
    		$-1.51$-0.79-91.14%Miss-84.1%
    Dec 23
    Reported Feb 15
    		$-0.94$-0.92-2.17%Miss+8.7%
    Sep 23
    Reported Nov 7
    		$2.27$0.04+5575.00%Beat+398.7%
    Jun 23
    Reported Aug 3
    		$-0.77$-0.93+17.20%Beat-18.5%
    Mar 23
    Reported May 4
    		$-0.82$-1.03+20.39%Beat+0.0%
    Dec 22
    Reported Feb 23
    		$-1.03$-1.07+3.74%Beat-68.9%
    Sep 22
    Reported Oct 27
    		$-0.76$-0.70-8.57%Miss-484.6%
    Jun 22
    Reported Aug 4
    		$-0.65$-0.70+7.14%Beat-66.7%
    Mar 22
    Reported May 5
    		$-0.82$-0.73-12.33%Miss-49.1%
    Dec 21
    Reported Feb 24
    		$-0.61$-0.50-22.00%Miss-27.1%
    Sep 21
    Reported Oct 28
    		$-0.13N/A+72.92%Beat-18.2%
    Jun 21
    Reported Jul 29
    		$-0.39$-0.50+22.00%Beat-77.3%
    Mar 21
    Reported May 6
    		$-0.55$-0.30-83.33%Miss-175.0%
    Dec 20
    Reported Mar 1
    		$-0.48$-0.47-2.13%Miss-84.6%
    Sep 20
    Reported Nov 5
    		$-0.11N/A+62.07%Beat+83.3%
    Jun 20
    Reported Jul 30
    		$-0.22$-0.36+38.89%Beat+62.1%
    Mar 20
    Reported May 11
    		$-0.20N/A+61.54%Beat+68.3%
    Dec 19
    Reported Feb 24
    		$-0.26$-0.37+29.73%Beat-44.4%
    Sep 19
    Reported Oct 30
    		$-0.66$-0.60-10.00%Miss+2.9%
    Jun 19
    Reported Aug 6
    		$-0.58$-0.40-45.00%Miss-132.0%
    Mar 19
    Reported May 7
    		$-0.63$-0.36-75.00%Miss-350.0%
    Dec 18
    Reported Feb 26
    		$-0.18N/A+62.50%Beat+60.0%
    Sep 18
    Reported Nov 1
    		$-0.68$-0.26-161.54%Miss-553.3%
    Jun 18
    Reported Jul 26
    		$-0.25$-0.11-127.27%Miss-933.3%
    Mar 18
    Reported May 1
    		$-0.14N/A+61.11%Beat-1500.0%
    Dec 17
    Reported Feb 27
    		$-0.45$-0.19-136.84%Miss-95.7%
    Sep 17
    Reported Nov 7
    		$0.15$-0.04+475.00%Beat-
    Jun 17
    Reported Aug 9
    		$0.03$0.03+0.00%Beat-
    Mar 17
    Reported May 4
    		$0.01N/A+103.85%Beat-
    Dec 16
    Reported Mar 1
    		$-0.23$-0.26+11.54%Beat-

    Key Metrics

    Valuation
    P/E Ratio82.48EV/EBITDA939.08x
    Price/FCF168.19xFCF Yield0.59%
    Profitability
    Profit Margin-7.35%Operating Margin2.33%
    ROE-236.40%ROIC-9.09%
    Financial Health
    Debt/Equity24.83xInterest Coverage-6.07x
    Current Ratio4.05xQuick Ratio3.99x
    Trading Statistics
    Beta1.14Avg Volume1.95M
    52-Week High$68.7352-Week Low$22.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$53.81
    SMA 20$57.06
    SMA 50$61.63
    SMA 200$45.76
    EMA 10$54.05
    EMA 20$56.45
    EMA 50$58.61
    EMA 200$48.49

    MACD

    Line: -2.84Signal: -2.41Hist: -0.43

    ADX

    ADX: 32.7+DI: 17.6-DI: 24.5

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down92.0
    PSAR$51.38

    Bollinger Bands

    Upper Band$64.80
    Lower Band$49.32
    %B Position2714%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    32.7

    Momentum Oscillators

    Stoch %K11.8
    Stoch %D8.7
    Williams %R-86.6
    ROC (10d)-7.1%
    Momentum-4.06
    CCI (20d)-75.2
    MFI (14d)33.6

    Volatility Measures

    ATR (14d)$2.35(4.4%)
    StdDev (20d)3.87
    Hist Vol35.4%(Moderate)

    Volume Flow

    VWAP$53.66
    OBV21.3M
    AD Line50.6M
    CMF (20d)-0.294

    Volume Metrics

    Avg Vol (20d)2.0M
    Vol Ratio1.0x
    VWMA (20d)$57.00

    Pivot Points

    R3$56.71
    R2$55.32
    R1$54.30
    Pivot Point$52.91
    S1$51.89
    S2$50.50
    S3$49.48

    Advanced Oscillators

    TSI-34.94
    Ultimate Osc30.2
    KST-151.00

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$169.58M$127.20M$129.69M$164.86M$114.45M$81.73M$74.79M$62.90M$54.12M$41.37M$45.06M$37.09M
    Cost of Revenue$2.17M$26.77M$2.55M$1.58M$1.52M$4.68M$2.55M$1.63M$12.41M$1.50M$16.42M$1.29M
    Gross Profit$167.41M$100.43M$127.14M$163.27M$112.93M$77.05M$72.23M$61.27M$41.71M$39.87M$28.64M$35.81M
    Operating Expenses$163.46M$137.35M$159.56M$138.34M$125.58M$119.73M$132.97M$117.42M$108.76M$179.11M$111.48M$128.39M
    R&D$60.28M$57.09M$57.87M$51.89M$49.36M$46.89M$62.07M$51.68M$54.33M$114.63M$58.75M$60.59M
    SG&A$96.11M$80.25M$101.69M$86.45M$76.22M$72.84M$69.50M$65.62M$64.78M$64.22M$63.59M$67.80M
    Operating Income$3.95M$-36,915,000$-32,428,000$24.93M$-12,650,000$-42,674,000$-60,737,000$-56,149,000$-67,051,000$-139,237,000$-82,839,000$-92,585,000
    Interest Income$3.36M$2.58M$2.59M$3.05M$3.29M$3.79M$3.79M$3.57M$4.42M$6.03M$7.15M$5.84M
    Interest Expense$2.13M$2.30M$2.30M$2.75M$2.85M$2.86M$2.82M$2.78M$2.79M$2.80M$2.82M$2.82M
    Income Before Tax$-35,001,000$-36,722,000$-21,065,000$25.71M$-12,735,000$-41,187,000$-60,340,000$-54,836,000$-69,567,000$-135,767,000$-88,528,000$-89,229,000
    Income Tax Expense$-204,000$-120,000$921,000$8,000$20,000$39,000$-72,000$-84,000$85,000$191,000$68,000$12,000
    Net Income$-34,797,000$-37,102,000$2.73M$25.71M$-12,755,000$-41,226,000$-60,264,000$-54,811,000$-70,409,000$-136,061,000$-90,173,000$150.74M
    EBITDA$-28,633,000$-9,210,000$-632,000$44.25M$4.13M$-25,528,000$-45,430,000$-40,820,000$-56,434,000$-123,087,000$-73,855,000$-74,933,000
    EBIT$-32,867,000$-34,422,000$-18,769,000$28.46M$-9,889,000$-38,330,000$-57,523,000$-52,059,000$-66,779,000$-132,967,000$-85,707,000$-86,408,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TVTX

    Government Contracts

    Gov Obligations (TTM)
    $337025
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    9
    New Awards (TTM)
    9
    Avg Remaining Term
    6.2 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26226N0373Department of Veterans AffairsDepartment of Veterans Affairs$131523Feb 10, 2026
    36C24526N0779Department of Veterans AffairsDepartment of Veterans Affairs$33372Jul 30, 2026
    36C24526N0571Department of Veterans AffairsDepartment of Veterans Affairs$33372May 7, 2026
    36C24526N0284Department of Veterans AffairsDepartment of Veterans Affairs$31408Jan 29, 2026
    36C24526N0130Department of Veterans AffairsDepartment of Veterans Affairs$28975Nov 5, 2025
    36C24525N0858Department of Veterans AffairsDepartment of Veterans Affairs$28975Aug 1, 2025
    36C24526N0554Department of Veterans AffairsDepartment of Veterans Affairs$17667Apr 29, 2026
    36C24526N0725Department of Veterans AffairsDepartment of Veterans Affairs$15867Jul 10, 2026
    36C24526N0675Department of Veterans AffairsDepartment of Veterans Affairs$15867Jun 24, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Form 144 TRAVERE THERAPEUTICS For: 15 October By Investing.com

    This article from Investing.com announces the filing of Form 144 for Travere Therapeutics (TVTX) on October 15. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal detail beyond...

    Investing.com India•10/15/26•Neutral

    An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX).

    Eric Dube, a director and officer at Travere Therapeutics (TVTX), has proposed selling 243,735 common shares, valued at approximately $12.98 million, with an approximate sale date of October 15...

    Stock Titan•10/15/26•Neutral

    TVTX Q3'26 Earnings: revenue estimate is 195.68M USD

    Travere Therapeutics, Inc. (TVTX) is scheduled to announce its Q3'26 earnings on October 22nd, with an estimated revenue of $195.68 million and an anticipated EPS of $0.03. The article provides a table detailing reported...

    TradingView•10/15/26•Neutral

    Learn Why The Bull Case For Travere Therapeutics Stock Could Change Following FILSPARI Kidney Data

    Travere Therapeutics shared positive FILSPARI data at ASN Kidney Week 2026, including strong remission rates in IgA nephropathy and FSGS...

    Simply Wall Street•10/15/26•Bullish

    Learn Why The Bull Case For Travere Therapeutics Stock Could Change Following FILSPARI Kidney Data

    Travere Therapeutics' FILSPARI drug presented positive data at ASN Kidney Week 2026, reinforcing its potential for IgA nephropathy and FSGS treatment. The data...

    Simply Wall Street•10/15/26•Somewhat-Bullish

    TVTX Valuation and Fair Value

    P/E
    82.5x
    Forward P/E
    39.8x
    EV/EBITDA
    939.1x
    P/FCF
    168.2x
    P/B
    201.2x
    See GNG's fair value

    TVTX Profitability: Margins, ROIC and FCF

    Gross margin
    94.4%
    Operating margin
    2.3%
    Net margin
    -7.3%
    ROIC
    -9.1%
    ROE
    -236.4%
    FCF margin
    5.0%
    FCF yield
    0.6%

    TVTX Competitors

    CompanyTicker
    PTC Therapeutics IncPTCT
    Terns Pharmaceuticals IncTERN
    Sotera Health CoSHC
    Cogent Biosciences IncCOGT
    Oruka Therapeutics, Inc.ORKA
    Grifols SA ADRGRFS
    Erasca IncERAS
    Crispr Therapeutics AGCRSP

    Sector: Healthcare

    TVTX Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    2
    Buy
    12
    Hold
    1
    Sell
    0
    Strong Sell
    0

    TVTX Bull Case vs Bear Case

    Bull case

    • TVTX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • TVTX grew quarterly revenue 48.2% year over year.
    • 93.3% of TVTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • TVTX trades at 82.5x trailing earnings.
    • TVTX has a -7.3% net profit margin.
    • TVTX has a debt-to-equity ratio of 24.8x.

    TVTX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    268.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.49
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About TVTX

    Does TVTX pay dividends?

    Travere Therapeutics Inc (TVTX) does not currently pay a regular dividend.

    What is TVTX's P/E ratio?

    Travere Therapeutics Inc has a price-to-earnings (P/E) ratio of 82.48.

    What is TVTX's market cap?

    Travere Therapeutics Inc (TVTX) has a market capitalization of $4.95B with a current stock price of $52.79.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In